ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Pharmaceuticals

Fujifilm starts clinical trial on Avigan for coronavirus

Company also says it is ready to ramp up production of the anti-flu medication

Tablets of Avigan shown in 2014. The anti-flu drug, made by a Fujifilm unit, is now in the spotlight as a possible coronavirus treatment   © Reuters

TOKYO -- Fujifilm Holdings announced Tuesday the start of a clinical trial for its flu-fighting drug Avigan to treat COVID-19, in which it will be administered to about 100 patients in Japanese hospitals to gauge safety and efficacy.

Some doctors in Japan are already using the medication to treat coronavirus patients for test purposes, but company-led clinical trials are a must to gain its approval for wide distribution.

Avigan showed promise as a coronavirus treatment in Chinese trials, though some previous studies found possible side effects, including fetal deaths or deformities.

Fujifilm is also preparing to increase production of Avigan, after Japanese Prime Minister Shinzo Abe expressed support for using it as a coronavirus treatment.

The Japanese government has a strategic reserve of 2 million doses of Avigan, but this might not be enough for all coronavirus patients.

Fujifilm restarted production of Avigan in early March. To raise output, the company is asking for help from raw material suppliers and is considering outsourcing part of the manufacturing process.

Avigan, developed by Toyama Chemical, gained attention earlier in March, after a Chinese official said clinical trials indicated the drug is effective in treating the coronavirus.

Abe suggested on Saturday that Japan would follow China's lead in considering Avigan as a coronavirus treatment, saying Japan "will expand clinical research" on Avigan and "start increasing drug production."

"We also plan to launch the clinical trial process required for formal approval [of treatments for] novel-coronavirus infection," Abe added.

Abe spoke with World Health Organization Director-General Tedros Adhanom Ghebreyesus by phone Monday, where the Japanese leader explained that the country will be conducting clinical trials for Avigan for it to be officially approved as a coronavirus drug.

Tedros said that the WHO is determined to coordinate among countries to develop various drugs and vaccines for the coronavirus.

Avigan was approved by Japanese regulators in 2014. But unlike other flu drugs such as Tamiflu, it has not been in continuous production because it is only used to treat new or reemerging influenza viruses, and at the request of the health minister.

Earlier in March the Chinese government said Avigan proved effective against the virus in clinical trials. No obvious side effects were reported. However, some researchers have warned Avigan needs to be used with great care because it can cause serious fetal abnormalities if taken by pregnant women.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more